Rheumatology Therapeutics Market Trends, 2017-2025

Rheumatology Therapeutics Market (Drug Class - Disease Modifying Anti-rheumatic Drugs (DMARD’s), Nonsteroidal Anti-inflammatory Drugs (NSAID’s), Corticosteroids, and Uric Acid Drugs; Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, and Ankylosing Spondylitis; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025

Rheumatology illnesses mostly affect the body's supporting or linking structures, such as muscles, ligaments, joints, and tendons, as well as a few organs. In some forms of rheumatic illness, this condition is characterized by joint inflammation and affects the spine. There are about a hundred different forms of rheumatic illness. It is caused by a variety of hereditary and environmental causes, including a poor diet and a change in lifestyle, all of which can lead to rheumatic disorders. Rheumatology illnesses include ankylosing spondylitis, fibromyalgia, gout, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, reactive arthritis, and scleroderma. Rheumatology treatment includes exercises, drugs, and physical therapy, as well as surgery to repair joint injury. Increasing prevalence of rheumatology illnesses is estimated to bolster growth of the global rheumatology therapeutics market in the years to come. The management of rheumatologic symptoms can be aided by early intervention. For the treatment of rheumatologic illness, doctors use disease-modifying antirheumatic medicines (DMARDs). Rheumatology illnesses can be cured with appropriate nutrition, exercise, and medicine.

Increased spending in the healthcare business for funding research and development activities, together with technological improvements in the pharmaceutical area is expected boost sales in the global market. Fitness is becoming more popular throughout the world, which is likely to help the global rheumatology therapeutics market develop. The global market is growing due to rising healthcare spending among the middle-income population.

Global Rheumatology Therapeutics

Rising Prevalence of Rheumatoid Arthritis amongst Women to Open up Growth Avenues

The treatment of rheumatic disorders, especially rheumatology therapies, is gaining in popularity amongst medical researchers and pharmaceutical companies throughout the world. The high prevalence of rheumatoid arthritis (RA), particularly amongst women, is likely to drive R&D in the rheumatic medicines industry. When the condition advances, RA causes persistent inflammation of the synovial membrane, which leads to joint damage. Overall, this has a negative influence on the quality of life of those who are impacted. In the treatment of RA, a variety of medication classes have arisen, the most notable of which are Disease Modifying Anti-Rheumatic Drugs (DMARDs). International organizations have been involved in establishing guidelines for pharmaceutical and non-pharmacological therapy, particularly for RA. The European League against Rheumatism is a good example (EULAR). Drug classifications are diverse and complicated.

Glucocorticoids (GC) are frequently used to control illness flare-ups and minimize disease severity. Improved synthetic DMARDs are the focus of new therapy recommendations. For instance, if a DMARD fails to work as a first-line treatment, physicians are looking towards biologic DMARDs. In the next few years, different tactics being attempted in the global rheumatology therapeutics market with the use of bDMARD are projected to enhance the landscape.

The emergence of biosimilars, on the other hand, is a key stumbling block for the global rheumatology therapeutics market. The rising demand for biosimilars may put a halt to the treatment of rheumatic disorders using traditional drugs. The rheumatic therapeutics industry is also being hampered by the patent expiration of various medications used to treat rheumatologist illnesses. For example, the Enbrels drug's patent expired in 2012.

Rise in Elderly Population in North America to Foster Growth of the Regional Market

Due to the substantial growth in the elderly population, which is plagued with various forms of rheumatic problems, North America is estimated to hold a significant share of the global rheumatology therapeutics market. In addition to that, the region's market has benefited from the use of biosimilars and biologics for the management of moderate to severe rheumatoid arthritis, as well as well-established healthcare facilities. In terms of market size, Europe lags behind North America. However, Asia Pacific is expected to dominate in terms of growth rate. This is due to the large number of people with rheumatoid arthritis and osteoarthritis, rising per capita healthcare spending, and the regulatory clearance of biosimilars for the treatment of a variety of rheumatic conditions.

Merck & Co., Inc., AbbVie, Inc., Bristol-Myers Squibb Company,  Pfizer, Inc., and other prominent firms operating in the global rheumatology therapeutics market is likely to account for majority share in the global rheumatology therapeutics market during the forecast period.  Takeda Pharmaceutical, Amgen, Inc., Genentech, Inc., Novartis AG, Janssen Biotech, Inc., and  Sanofi are among the other global participants in the industry.

Global Rheumatology Therapeutics Market is segmented as given below:

by Drug Class

  • Disease Modifying Anti-rheumatic Drugs (DMARD’s)
    • Synthetic Disease Modifying Anti-rheumatic Drugs
    • Biologic Disease Modifying Anti-rheumatic Drugs
  • Nonsteroidal Anti-inflammatory Drugs (NSAID’s)
  • Corticosteroids
  • Uric Acid Drugs
  • Others

by Disease Indication

  • Rheumatoid Arthritis
  • Osteoarthritis
  • Gout
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Others

by Route of Administration

  • Parenteral Route
  • Oral Route
  • Topical

by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

by Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of rheumatology therapeutics market?

Rheumatology therapeutics market is expected to attain value of a US$ 52.96 bn by the end of 2025

What is the anticipated CAGR of the rheumatology therapeutics market in the forecast period?

Rheumatology therapeutics market is expected to expand with a CAGR of 2.7% over the forecast period from 2017 to 2025

What are the key driving factors for the growth of the rheumatology therapeutics market?

Rheumatology therapeutics market is driven by increasing expenditure on healthcare from mid-earing population and rising prevalence of rheumatology diseases

Which region is expected to project the highest market share in the global rheumatology therapeutics market?

North America accounts for a leading share in the global rheumatology therapeutics market owing to rapid rise in the elderly population

Who are the key players in the global rheumatology therapeutics market?

Key players operating in the global rheumatology therapeutics market include AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Merck & Co., Inc., Amgen, Inc., Novartis AG, Janssen Biotech, Inc., Sanofi, Genentech, Inc.

    Chapter 1. Preface
    1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    Chapter 2. Assumptions and Research Methodology

    Chapter 3. Executive Summary: Global Rheumatology Therapeutics  market

    Chapter 4. Market Overview
    4.1. Introduction
                4.1.1. Key Industry Developments
                4.1.2. Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, 2015–2025
                4.1.3. Global Rheumatology Therapeutics Market Outlook

    Chapter 5. Market Dynamics
         5.1. Drivers
         5.2. Restraints
         5.3. Opportunities
         5.4. Porter’s five forces analysis

    Chapter 6. Rheumatology Therapeutics Market Analysis and Forecast, by Drug Class
         6.1. Key Findings
         6.2. Introduction
         6.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
                6.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                         6.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
                         6.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
                6.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
                6.3.3. Corticosteroids
                6.3.4. Uric Acid Drugs
                6.3.5. Others
         6.4. Market Attractiveness Analysis, by Drug Class
         6.5. Key Trends

    Chapter 7. Global Rheumatology Therapeutics Market  Analysis and Forecasts, by Disease Indication
         7.1. Key Findings
         7.2. Introduction
         7.3. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
                7.3.1. Rheumatoid Arthritis
                7.3.2. Osteoarthritis
                7.3.3. Gout
                7.3.4. Psoriatic Arthritis
                7.3.5. Ankylosing Spondylitis
                7.3.6.  Others
         7.4. Market Attractiveness Analysis, by Disease Indication
         7.5. Key Trends

    Chapter 8. Global Rheumatology Therapeutics Market  Analysis and Forecasts, by Route of Administration
         8.1. Key Findings
         8.2. Introduction
         8.3. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
                8.3.1. Parenteral
                8.3.2. Oral
                8.3.3. Topical
         8.4. Market Attractiveness Analysis, by Route of Administration
         8.5. Key Trends

    Chapter 9. Global Rheumatology Therapeutics Market  Analysis and Forecasts, by Distribution Channel
         9.1. Key Findings
         9.2. Introduction
         9.3. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
                9.3.1. Hospital Pharmacy
                9.3.2. Retail Pharmacy
                9.3.3. Online Pharmacy
         9.4. Market Attractiveness Analysis, by Distribution Channel
         9.5. Key Trends

    Chapter 10. Global Rheumatology Therapeutics market  Analysis and Forecasts, by Region
         10.1. Key Findings
         10.2.   Global Market Scenario
         10.3.   Market Value (US$ Mn) Forecast, by Region, 2017-2025
                10.3.1. North America
                10.3.2. Europe
                10.3.3. Asia Pacific
                10.3.4. Latin America
                10.3.5. Middle East & Africa
         10.4. Market Attractiveness Analysis, by Region

    Chapter 11. North America Rheumatology Therapeutics market  Analysis and Forecast
         11.1. Key Findings
         11.2. Market size  (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
                11.2.1. U.S.
                11.2.2. Canada
         11.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
                11.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                         11.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
                         11.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
                11.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
                11.3.3. Corticosteroids
                11.3.4. Uric Acid Drugs
                11.3.5. Others
         11.4. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
                11.4.1. Rheumatoid Arthritis
                11.4.2. Osteoarthritis
                11.4.3. Gout
                11.4.4. Psoriatic Arthritis
                11.4.5. Ankylosing Spondylitis
                11.4.6.  Others
         11.5. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
                11.5.1. Parenteral
                11.5.2. Oral
                11.5.3. Topical
         11.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
                11.6.1. Hospital Pharmacy
                11.6.2. Retail Pharmacy
                11.6.3. Online Pharmacy
         11.7. Market Attractiveness Analysis
                11.7.1. By Country/Sub-region
                11.7.2. By Drug Class
                11.7.3. By Disease Indication
                11.7.4. By Route of Administration
                11.7.5. By Distribution Channel
         11.8. Key Trends

    Chapter 12. Europe Rheumatology Therapeutics market  Analysis and Forecast
         12.1. Key Findings
         12.2. Market size (US$ Mn) Forecast By Country, 2017-2025
                12.2.1. Germany
                12.2.2. U.K.
                12.2.3. France
                12.2.4. Italy
                12.2.5. Spain
                12.2.6. Russia
                12.2.7. Rest of Europe
         12.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
                12.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                         12.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
                         12.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
                12.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
                12.3.3. Corticosteroids
                12.3.4. Uric Acid Drugs
                12.3.5. Others
         12.4. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
                12.4.1. Rheumatoid Arthritis
                12.4.2. Osteoarthritis
                12.4.3. Gout
                12.4.4. Psoriatic Arthritis
                12.4.5. Ankylosing Spondylitis
                12.4.6.  Others
         12.5. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
                12.5.1. Parenteral
                12.5.2. Oral
                12.5.3. Topical
         12.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
                12.6.1. Hospital Pharmacy
                12.6.2. Retail Pharmacy
                12.6.3. Online Pharmacy
         12.7. Market Attractiveness Analysis
                12.7.1. By Country/Sub-region
                12.7.2. By Drug Class
                12.7.3. By Disease Indication
                12.7.4. By Route of Administration
                12.7.5. By Distribution Channel
         12.8. Key Trends

    Chapter 13. Asia Pacific Rheumatology Therapeutics market Analysis and Forecast
         13.1. Key Findings / Developments
         13.2. Market Overview
         13.3. Market size (US$ Mn) Forecast, by Country, 2017-2025
                13.3.1. China
                13.3.2. India
                13.3.3. Japan
                13.3.4. Australia & New Zealand
                13.3.5. Rest of Asia Pacific
         13.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
                13.4.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                         13.4.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
                         13.4.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
                13.4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
                13.4.3. Corticosteroids
                13.4.4. Uric Acid Drugs
                13.4.5. Others
         13.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
                13.5.1. Rheumatoid Arthritis
                13.5.2. Osteoarthritis
                13.5.3. Gout
                13.5.4. Psoriatic Arthritis
                13.5.5. Ankylosing Spondylitis
                13.5.6.  Others
         13.6. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
                13.6.1. Parenteral
                13.6.2. Oral
                13.6.3. Topical
         13.7. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
                13.7.1. Hospital Pharmacy
                13.7.2. Retail Pharmacy
                13.7.3. Online Pharmacy
         13.8. Market Attractiveness Analysis
                13.8.1. By Country/Sub-region
                13.8.2. By Drug Class
                13.8.3. By Disease Indication
                13.8.4. By Route of Administration
                13.8.5. By Distribution Channel
         13.9. Key Trends

    Chapter 14. Latin America Rheumatology Therapeutics market Analysis and Forecast
         14.1. Key Findings / Developments
         14.2. Market Overview
         14.3. Market Size (US$ Mn) Forecast, by Country, 2017-2025
                14.3.1. Brazil
                14.3.2. Mexico
                14.3.3. Rest of Latin America
         14.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
                14.4.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                         14.4.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
                         14.4.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
                14.4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
                14.4.3. Corticosteroids
                14.4.4. Uric Acid Drugs
                14.4.5. Others
         14.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
                14.5.1. Rheumatoid Arthritis
                14.5.2. Osteoarthritis
                14.5.3. Gout
                14.5.4. Psoriatic Arthritis
                14.5.5. Ankylosing Spondylitis
                14.5.6.  Others
         14.6. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
                14.6.1. Parenteral
                14.6.2. Oral
                14.6.3. Topical
         14.7. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
                14.7.1. Hospital Pharmacy
                14.7.2. Retail Pharmacy
                14.7.3. Online Pharmacy
         14.8. Market Attractiveness Analysis
                14.8.1. By Country/Sub-region
                14.8.2. By Drug Class
                14.8.3. By Disease Indication
                14.8.4. By Route of Administration
                14.8.5. By Distribution Channel
         14.9. Key Trends

    Chapter 15. Middle East and Africa Rheumatology Therapeutics market Analysis and Forecast
         15.1. Key Findings / Developments
         15.2. Market Overview
         15.3. Market size (US$ Mn) Forecast, by Country, 2017-2025
                15.3.1. GCC Countries
                15.3.2. South Africa
                15.3.3. Israel
                15.3.4. Rest of Middle East and Africa
         15.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
                15.4.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                         15.4.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
                         15.4.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
                15.4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
                15.4.3. Corticosteroids
                15.4.4. Uric Acid Drugs
                15.4.5. Others
         15.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
                15.5.1. Rheumatoid Arthritis
                15.5.2. Osteoarthritis
                15.5.3. Gout
                15.5.4. Psoriatic Arthritis
                15.5.5. Ankylosing Spondylitis
                15.5.6.  Others
         15.6. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
                15.6.1. Parenteral
                15.6.2. Oral
                15.6.3. Topical
         15.7. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
                15.7.1. Hospital Pharmacy
                15.7.2. Retail Pharmacy
                15.7.3. Online Pharmacy
         15.8. Market Attractiveness Analysis
                15.8.1. By Country/Sub-region
                15.8.2. By Drug Class
                15.8.3. By Disease Indication
                15.8.4. By Route of Administration
                15.8.5. By Distribution Channel
         15.9. Key Trends

    Chapter 16. Competition Landscape
         16.1. Global rheumatology therapeutics Market Share, by Company, 2016
         16.2. Market Player – Competition Matrix (By Tier and Size of companies)
         16.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
                16.3.1. Amgen, Inc.
                         16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                         16.3.1.2. Product Portfolio
                         16.3.1.3. SWOT Analysis
                         16.3.1.4. Strategic Overview
                16.3.2. AbbVie, Inc.
                         16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                         16.3.2.2. Product Portfolio
                         16.3.2.3. SWOT Analysis
                         16.3.2.4. Strategic Overview
                16.3.3. Pfizer, Inc.
                         16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                         16.3.3.2. Product Portfolio
                         16.3.3.3. SWOT Analysis
                         16.3.3.4. Financial Overview
                         16.3.3.5. Strategic Overview
                16.3.4. Janssen Biotech, Inc. (Johnson & Johnson)
                         16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                         16.3.4.2. Product Portfolio
                         16.3.4.3. SWOT Analysis
                         16.3.4.4. Financial Overview
                         16.3.4.5. Strategic Overview
                16.3.5. Novartis AG
                         16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                         16.3.5.2. Product Portfolio
                         16.3.5.3. SWOT Analysis
                         16.3.5.4. Financial Overview
                         16.3.5.5. Strategic Overview
                16.3.6. Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
                         16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                         16.3.6.2. Product Portfolio
                         16.3.6.3. SWOT Analysis
                         16.3.6.4. Financial Overview
                         16.3.6.5. Strategic Overview
                16.3.7. Bristol-Myers Squibb Company
                         16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                         16.3.7.2. Product Portfolio
                         16.3.7.3. SWOT Analysis
                         16.3.7.4. Financial Overview
                         16.3.7.5. Strategic Overview
                16.3.8. Merck & Co., Inc.
                         16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                         16.3.8.2. Product Portfolio
                         16.3.8.3. SWOT Analysis
                         16.3.8.4. Financial Overview
                         16.3.8.5. Strategic Overview
                16.3.9. Sanofi
                         16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                         16.3.9.2. Product Portfolio
                         16.3.9.3. SWOT Analysis
                         16.3.9.4. Financial Overview
                         16.3.9.5. Strategic Overview
                16.3.10. Takeda Pharmaceutical
                         16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                         16.3.10.2. Product Portfolio
                         16.3.10.3. SWOT Analysis
                         16.3.10.4. Financial Overview
                         16.3.10.5. Strategic Overview

     

    List of Tables

    Table 01: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 02: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
    Table 03: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
    Table 04: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 05: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 06: Global rheumatology therapeutics Market Size (US$ Mn) Forecast, by Region, 2015–2025
    Table 07: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 08: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 09: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
    Table 10: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
    Table 11: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 12: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 13: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 14: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 15: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
    Table 16: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
    Table 17: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 18: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 19: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 20: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 21: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
    Table 22: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
    Table 23: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 24: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 25: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 26: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 27: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
    Table 28: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
    Table 29: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 30: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 31: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 32: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 33: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
    Table 34: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
    Table 35: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 36: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025

    List of Figures

    Figure 01: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, 2015–2025
    Figure 02: Market Value Share, by Drug Class (2016)
    Figure 03: Market Value Share, by Disease Indication (2016)
    Figure 04: Market Value Share, by Route of Administration (2016)
    Figure 05: Market Value Share, by Distribution Channel (2016)
    Figure 06: Market Value Share, by Region (2016)
    Figure 07: Global Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
    Figure 08: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
    Figure 09: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Non-steroidal Anti-inflammatory Drugs (NSAIDs), 2015–2025
    Figure 10: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Corticosteroids, 2015–2025
    Figure 11: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Uric Acid Drugs, 2015–2025
    Figure 12: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2015–2025
    Figure 13: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
    Figure 14: Global Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
    Figure 15: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Rheumatoid Arthritis, 2015–2025
    Figure 16: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Osteoarthritis, 2015–2025
    Figure 17: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Gout, 2015–2025
    Figure 18: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Psoriatic Arthritis, 2015–2025
    Figure 19: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Ankylosing Spondylitis, 2015–2025
    Figure 20: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2015–2025
    Figure 21: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
    Figure 22: Global Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
    Figure 23: Global Rheumatology Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Oral, 2015-2025
    Figure 24: Global rheumatology therapeutics market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Parenteral, 2015–2025
    Figure 25: Global Rheumatology Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Topical, 2015-2025
    Figure 26: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
    Figure 27: Global Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
    Figure 28: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacy, 2015–2025
    Figure 29: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacy, 2015–2025
    Figure 30: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacy, 2015-2025
    Figure 31: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 32: Global rheumatology therapeutics Market Value Share Analysis, by Region, 2017 and 2025
    Figure 33: Global rheumatology therapeutics Market Attractiveness Analysis, by Region, 2017-2025
    Figure 34: North America Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
    Figure 35: North America Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
    Figure 36: North America Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
    Figure 37: North America Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
    Figure 38: North America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
    Figure 39: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
    Figure 40: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
    Figure 41: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
    Figure 42: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
    Figure 43: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 44: Europe Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
    Figure 45: Europe Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
    Figure 46: Europe Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
    Figure 47: Europe Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
    Figure 48: Europe Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
    Figure 49: Europe Rheumatology Therapeutics Market Attractiveness analysis, by Country/Sub-region, 2017–2025
    Figure 50: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
    Figure 51: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
    Figure 52: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
    Figure 53: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 54: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
    Figure 55: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
    Figure 56: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
    Figure 57: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
    Figure 58: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
    Figure 59: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
    Figure 60: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
    Figure 61: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
    Figure 62: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
    Figure 63: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 64: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
    Figure 65: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
    Figure 66: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
    Figure 67: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
    Figure 68: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
    Figure 69: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
    Figure 70: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
    Figure 71: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
    Figure 72: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
    Figure 73: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 74: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
    Figure 75: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
    Figure 76: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
    Figure 77: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
    Figure 78: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
    Figure 79: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
    Figure 80: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
    Figure 81: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
    Figure 82: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
    Figure 83: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 84: Global rheumatology therapeutics Market Share, by Company, 2016

Copyright © Transparency Market Research, Inc. All Rights reserved